Mindwalk identified TDP-43 antibodies that selectively target abnormal protein clumps linked to ALS and other diseases.

University of Utah researchers at the Pulst-Scoles Laboratory have discovered that reducing levels of the STAUFEN-1 protein ...

Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.

On a quiet farm in Erie County, Pennsylvania, 67-year-old Diane Zaczyk used to think nothing of hefting 50-pound sacks of chicken feed onto her shoulder. Strong, stubborn and devoted to caring for her ...

Amyotrophic lateral sclerosis (ALS) is a devastating neurological disorder of unknown cause, in which motor nerve cells of the brain and spinal cord that transmit signals to muscles progressively ...

FAYETTEVILLE -- Even before Thursday's ceremonial ribbon-cutting for the new ALS Clinic at University of Arkansas for Medical Sciences Northwest Hospital, officials and representatives of the ALS ...

“Powerful” new treatments for various types of cancer and neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and ALS, will likely get rolled out within the next few years, Food and Drug ...

NEW YORK, Dec. 30, 2025 /PRNewswire/ -- ALS United Greater New York increased its financial investment in ALS research throughout 2025, accelerating new approaches in ALS treatment, prevention, and ...

After years of research, finally a potential answer as to what causes ALS. Amyotrophic lateral sclerosis is a deadly neuromuscular disease with no known cure. The muscles degrade leaving patients ...